Elad Sharon and Colleagues: How a Common Trait Unfairly Excludes Black Patients from Cancer Trials
Elad Sharon, Associated Professor of Medicine at Dana-Farber, shared a post on X:
“Very proud of this effort led by one of our former Dana-Farber fellows, Lauren Merz, on the Duffy null phenotype. Thanks to JAMA Oncology for highlighting! Important to see that many otherwise healthy patients are unfairly being excluded because of an arbitrary number… the National Cancer Institute”
Quoting JAMA Oncology’s post:
“Absolute neutrophil count–based eligibility criteria in cancer trials disproportionately exclude Black patients with the Duffy null phenotype, suggesting the need for Duffy status–specific thresholds to improve trial equity.”
Title: Duffy Null–Associated Absolute Neutrophil Counts and Cancer Clinical Trial Eligibility
Authors: Lauren E. Merz, Yating Wang, Angel Cronin, Elad Sharon, Thomas P. Walsh, Stephen P. Hibbs, Christopher S. Lathan, Andrew Hantel
Read full article here.
Never miss hematology updates with Hemostasis Today.
-
May 24, 2026, 07:39Shamala Thilarajah: Our Team Receives the NMRC Transition Award for NEUROACT-Stroke
-
May 24, 2026, 05:48Yazan Abou-Ismail: Contributing to the Future of von Willebrand Disease Management
-
May 24, 2026, 05:47Ali AlBahar: The Immunologic Complexity Behind ABO Blood Grouping
-
May 24, 2026, 05:46Ghaith Mansour: Honoring Scientific Collaboration at the 7th Pharmacy Research and Innovation Day
-
May 24, 2026, 04:57Ahmed Elsobky: Strengthening Hemophilia Care Under Egypt’s Universal Health Insurance System
-
May 24, 2026, 04:49Hussien Hishmat: There Is More to Pulmonary Embolism than Just Anticoagulation
-
May 24, 2026, 04:25Sarah Elkourashy: Diagnostic Challenges and Management Strategies for Maternal–Fetal Outcomes in TTP
-
May 24, 2026, 04:11Ayah Ghazi Al-Qasrawi: How Should Sepsis-Induced DIC Be Managed in Patients Receiving Thienopyridines
-
May 24, 2026, 04:05Kate Hayward: Recent Stroke Recovery and Rehabilitation Highlights